NCT02744222已完成2 期
An International Multicenter Double-blind Placebo-controlled Randomized Study to Compare the Efficacy, Safety and Tolerability of BCD-054 (JSC BIOCAD, Russia), 180 μg and 240 μg, Versus Avonex® (Biogen Idec Ltd., UK) in Patients With Relapsing-remitting Multiple Sclerosis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Biocad
- 入组人数
- 399
- 试验地点
- 1
- 主要终点
- Time to first relapse after 52 weeks of blinded treatment with BCD-054 or Avonex
研究概览
简要总结
An International Multicenter Double-blind Placebo-controlled Randomized Study to Compare the Efficacy, Safety and Tolerability of BCD-054 (JSC BIOCAD, Russia), 180 μg and 240 μg, versus Avonex® (Biogen Idec Ltd., UK) in Patients with Relapsing-remitting Multiple Sclerosis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent to participate in the study;
- •Men and women aged from 18 to 60 years (inclusive) on the day of signing informed consent;
- •Confirmed diagnosis of relapsing-remitting multiple sclerosis (according to McDonald criteria 2010) ;
- •Documentary evidence that within the last 12 months before signing informed consent the patient had:
- •At least 1 relapse, or
- •At least 1 Gadolinium enhancing T1-weighted lesion or 1 new T2-weighted lesion in dynamics.
- •The patient should be neurologically stable during 30 days before signing informed consent (i.e. the patient should not have any new or aggravated neurological symptoms, as told by the patient); or the patient's condition should be completely stabilized since the last relapse, and the duration of stabilization should be at least 30 days) ;
- •Patients of childbearing potential and their partners with preserved reproductive function must implement reliable contraceptive methods starting from signing informed consent to 4 weeks after the last dose of study therapy. This requirement does not apply to patients after operative sterilization. Reliable contraception methods include one barrier method in combination with one of the following: spermicides, intrauterine device/oral contraceptives;
- •Total EDSS score of 0 to 5.5 inclusive (assessed by the Assessing Neurologist).
排除标准
- •Primary or secondary progressive MS;
- •Other conditions (except for multiple sclerosis) that can affect the assessment of MS symptoms: to mask, aggravate, change symptoms of multiple sclerosis, result in clinical signs or laboratory instrumental findings suggesting multiple sclerosis;
- •A relapse during the screening period ;
- •Any acute infections, relapses of chronic infections or any other chronic diseases that are present on the day of signing informed consent and can, as judged by the Investigator, negatively affect the patient's safety during the study treatment;
- •HIV, hepatitis B, hepatitis C, or syphilis ;
- •Metabolic abnormalities (disorders) manifesting as:
- •baseline creatinine levels increased more than 2-fold vs. upper limit of normal;
- •baseline urea levels increased more than 3-fold vs. upper limit of normal;
- •baseline ALT, AST or GGT levels increased more than 2.5-fold vs. upper limit of normal;
- •baseline bilirubin levels increased more than 1.5-fold vs. upper limit of normal;
- •Baseline leukocyte counts lower than <3.0 × 109/L, platelet counts lower than <125 × 109/L or hemoglobin levels <100 g/L;
- •A history of severe depression, suicidal thoughts or suicide attempts ;
- •Signs of clinically significant depression (baseline Beck's score of more than 15);
- •A history of hypothyroidism/hyperthyroidism and/or baseline abnormalities of TSH levels vs. lower or upper limits of normal;
- •Pregnancy, lactation or planned pregnancy over the entire study period;
- •A history of use:
- •any time before signing informed consent: disease-modifying interferon beta drugs (interferon beta-1a, interferon beta-1b),
- •within 30 days before signing informed consent: glatiramer acetate;
- •within 6 months before signing informed consent: monoclonal antibodies, cytotoxic and/or immunosuppressive drugs, including but not limited to mitoxantrone, cyclophosphamide, cyclosporine, fingolimod, cladribine; or total lymphoid irradiation;
- •Systemic (i.v. or oral) corticosteroids used within 30 days before signing informed consent;
- •A history of intolerance of or allergy to pegylated proteins, interferon beta or other ingredients of BCD-054/Avonex®;
- •Known alcoholic or drug dependency or signs of present alcoholic/drug dependence that, in the Investigator's opinion, can be contraindications for study therapy of multiple sclerosis with interferon beta-1a or limit treatment compliance;
- •Inability to follow the Protocol procedures (in the Investigator's opinion).
- •Contraindications to MRI or use of gadolinium-containing contrast agents:
- •Metal foreign objects in the body: magnetic implants, ferromagnetic clips for cerebral vessels, artificial heart valves, electronic middle ear implants, pacemakers;
- •A history of allergy to gadolinium or gadolinium-containing contrast agents;
- •с) Fear of cramped spaces; d) Kidney function impairment with a risk of delayed gadolinium elimination (creatinine level increased to more than 2 x upper limit of normal); e) Documented diagnosis of sickle cell or hemolytic anemia, hemoglobinopathy.
- •Any malignancies or a history of malignancies, except for cured basal cell carcinoma or cervical cancer in situ;
- •Vaccination within 4 weeks before signing informed consent (as told by the patient);
- •Participation in other clinical studies within 90 months before signing informed consent.
结局指标
主要结局
Time to first relapse after 52 weeks of blinded treatment with BCD-054 or Avonex
时间窗: Week 52
Time to first relapse after 52 weeks of blinded treatment with BCD-054 or Avonex
次要结局
- Expanded Disability Status Scale (EDSS)(Week 20, Week 52, Week 104)
- Annual average frequency of relapses(Week 20, Week 52, Week 104)
- Proportion of relapse-free patients(Week 20, Week 52, Week 104)
- AUC (0-336 hours)(from 0 to 336 hours after the first full dose of BCD-054 or Avonex® (Week 4))
- Symbol Digit Modalities Test (SDMT)(Week 20, Week 52, Week 104)
- CUA(Week 20, Week 52, Week 104)
- Proportion of patients without contrast-enhancing lesions(Week 20, Week 52, Week 104)
- Number of new or enlarging T2-weighted lesions(Week 20, Week 52, Week 104)
- Proportion of patients without new or enlarging T2-weighted lesions(Week 20, Week 52, Week 104)
- 9-Hole Peg Test (9 HPT)(Week 20, Week 52, Week 104)
- The proportion of patients, in each group, who discontinued the study due to AEs/SAEs(Week12, Week 20, Week 52, Week 104)
- Changes in T2-weighted lesion volume(Week 20, Week 52, Week 104)
- Proportion of patients with sustained disability progression(Week 20, Week 52, Week 104)
- The proportion of patients, in each group, who developed СТСАЕ v. 4.03 Grade 3-4 AEs that, in the Investigator's opinion, are related to BCD-054 or Avonex®(Week12, Week 20, Week 52, Week 104)
- The proportion of BAb- and NAb-positive patients(Week 20, Week 52, Week 104)
- AUEC (0-168 hours)(from 0 to 168 hours after the first full dose of BCD-054 or Avonex® (Week 4))
- Changes in hypointense T1-weighted lesion volume(Week 20, Week 52, Week 104)
- Timed 25-Foot Walk(Week 20, Week 52, Week 104)
- The proportion of patients who developed AEs/SAEs that, in the Investigator's opinion, are related to BCD-054 or Avonex®(Week12, Week 20, Week 52, Week 104)
- AUC (0-168 hours)(from 0 to 168 hours after the first full dose of BCD-054 or Avonex® (Week 4))
- AUECss (0-168 hours, 0-336 hours)(from 0 to 168 hours and from 0 to 336 hours after isince the introduction of 17 injections)
- AUCss (0-168 hours, 0-336 hours)(from 0 to 168 hours and from 0 to 336 hours since the introduction of 17 injections)
- AUEC (0-336 hours)(from 0 to 336 hours after the first full dose of BCD-054 or Avonex® (Week 4))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in ChildrenAcute Respiratory Viral InfectionsNCT03039621Materia Medica Holding287
已完成
4 期
Efficacy And Safety Of Probiatop In The Treatment Of Digestive SymptomsSigns and Symptoms, DigestiveNCT05603403Azidus Brasil150
进行中（未招募）
2 期
Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic MelanomaMelanoma MetastaticMelanomaNCT03913923Biocad117
终止
不适用
A Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial InfarctionAcute Myocardial InfarctionNCT00529932Jozef Bartunek19
已完成
2 期
Study To Assess FRacTure Healing With SclerosTin Antibody - HipFracture HealingNCT01081678Amgen332